5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316780 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Karolina Łuczkowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education, Minister of Science and Higher Education.
Abstract (Originalsprache)
Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development of resistance to chemotherapy is one of the greatest challenges of modern oncology. Therefore, it is crucial to discover and implement new adjuvant therapies that can bypass therapeutic resistance. In this paper, we investigated the in vitro effect of methylation inhibitor 5-Aza-2′-deoxycytidine on the proliferative potential of MM cells and the development of resistance to BTZ. We demonstrate that alterations in the DNA methylation profile are associated with BTZ resistance. Moreover, the addition of methylation inhibitor 5-Aza-2′-deoxycytidine to BTZ-resistant MM cells led to a reduction in the proliferation of the BTZ-resistant phenotype, resulting in the restoration of sensitivity to BTZ. However, further in vitro and ex vivo studies are required before adjuvant therapy can be incorporated into existing treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland.
ORCID-Profile: Karolina Łuczkowska, Piotr Kulig, Bartłomiej Baumert
Förderung
- Ministry of Science and Higher Education
- Minister of Science and Higher Education
Zitieren
APA
Łuczkowska, K., Kulig, P., Rusińska, K., Baumert, B., & Machaliński, B. (2023). 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316780
Vancouver
Łuczkowska K, Kulig P, Rusińska K, Baumert B, Machaliński B. 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316780
BibTeX
@article{uczkowska2023,
author = {Łuczkowska, Karolina and Kulig, Piotr and Rusińska, Klaudia and Baumert, Bartłomiej and Machaliński, Bogusław},
title = {5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316780}
}
EUVIMED